Results 101 to 110 of about 9,514 (200)

The efficacy of the combination of venetoclax and hypomethylating agents versus HAG agents in patients with acute myeloid leukemia: a retrospective study

Hematology
Objectives: The purpose of this study was to compare the effectiveness of the combination of venetoclax and hypomethylating agents with the HAG regimen.Methods: We studied 52 cases of newly diagnosed AML and 26 cases of relapsed refractory AML ...
Fei Xin, Yan-Hui Yu, Xu-Liang Shen, Guo-Xiang Zhang   +3 more
doaj   +1 more source

Safety and efficacy of azacitidine in myelodysplastic syndromes

Drug Design, Development and Therapy, 2010
Carlos E Vigil, Taida Martin-Santos, Guillermo Garcia-ManeroDepartment of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USAPurpose: The clinical efficacy, different dosages, treatment schedules, and safety of azacitidine are ...
Carlos E Vigil, Taida Martin-Santos, Guillermo Garcia-Manero   +2 more
doaj  

Outcomes of patients with de novo and secondary acute myeloid leukaemia treated with front‐line hypomethylating agents and venetoclax: A retrospective Italian study

British Journal of Haematology, Volume 209, Issue 2, Page 799-803, August 2026.
Ilaria Tanasi, Edoardo Tamellini, Elena Marchetti, Eleonora De Bellis, Cristina Ancora, Francesco Angotzi, Davide Facchinelli, Francesca Capraro, Giulia Battaglia, Alessandra Sperotto, Michele Gottardi, Matteo Leoncin, Mauro Krampera, Mario Tiribelli, Carmela Gurrieri   +14 more
wiley   +1 more source

Early venetoclax dose escalation at minimal residual disease progression may benefit selected acute myeloid leukaemia patients

British Journal of Haematology, Volume 209, Issue 2, Page 793-798, August 2026.
Sari Kytölä, Anu Partanen, Milla E. L. Kuusisto, Sirpa Koskela, Annasofia Holopainen, Ida Vänttinen, Tanja Ruokoranta, Pia Ettala, Johanna Rimpiläinen, Timo Siitonen, Marja Pyörälä, Heikki Kuusanmäki, Mika Kontro   +12 more
wiley   +1 more source

Development of the treatment preference in myelodysplasia questionnaire for clinicians, carers, and patients

eJHaem
This study reports the development activities for the Treatment Preference Myelodysplasia Questionnaires (TPMQ) for clinicians (mTPMQ), carers (cTPMQ), and patients (pTPMQ).
Robert Morlock, Chun Fong, Francesco Castaldi, Taliesha Paine, Donna Collett, Anoop Enjeti   +5 more
doaj   +1 more source

Hypomethylating agents plus venetoclax in younger acute myeloid leukemia: Meta-analysis of a shifting treatment paradigm. [PDF]

Cancer
Perrone S, De Fazio L, Monachetti S, Molica M.   +3 more
europepmc   +1 more source

Gut Microbiota Alterations in Myelodysplastic Neoplasms Are Associated With Immune Dysfunction and the Therapeutic Mechanism of Hypomethylating Agents. [PDF]

Cancer Med
Shi Z, Huang F, Luo C, Yang L, Chen Y, Qiao C, Wang R, Wang Y, Yan Y, Wang L, Fan L, Shen W.   +11 more
europepmc   +1 more source

Venetoclax Plus Hypomethylating Agents for Treatment-Naïve Myelodysplastic Syndromes with Increased Blasts: A Prospective Multicenter Cohort Study. [PDF]

Blood Lymphat Cancer
Zhao N, Zhu L, Hu X, Tong J, Ge H, Ye L, Zhu X, Gai C, Feng Y, Zhang L, Wang L, Sun G, Xue L, Zhu X, Zheng C.   +14 more
europepmc   +1 more source

Rethinking the effectiveness of hypomethylating agents in myelodysplastic syndromes: the 50%-2-year wall. [PDF]

Haematologica
Oster H, Mittelman M.
europepmc   +1 more source

A Nomogram Prediction Model and Scoring System for Resistance in Acute Myeloid Leukemia Patients Treated with Venetoclax Combined with Hypomethylating Agents. [PDF]

Curr Oncol
Fan Q, Guo Y, Hui X, Zhang Y, Li J, Liang J, Wang Y.   +6 more
europepmc   +1 more source